Compare Merck & Co., Inc. (MRK) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Palo Alto Networks Inc — how do they compare? Merck & Co., Inc. trades at $131.42 (market cap $321.77B), while Palo Alto Networks Inc trades at $383.41 (market cap $312.80B). The key difference: Merck & Co., Inc. and Palo Alto Networks Inc are close in size by market cap, and Merck & Co., Inc. pays a 2.61% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| MRK | PANW | |
|---|---|---|
Market Cap | $321.77B | $312.80B |
Sector | Health | Technology |
52-Week High | $131.84 | $385.04 |
52-Week Low | $77.60 | $141.67 |
Enterprise Value | $368.53B | $311.76B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Palo Alto Networks (PANW) trades at $385.04, up 5.82% over the past day, reflecting strong momentum amid positive sentiment around AI-driven cybersecurity demand. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, while RSI levels suggest potential overbought conditions. Fundamentally, the company reported revenue of $9.22B in 2025 with a net income margin of 7.95%, though valuation ratios like P/E of 333.74 indicate a premium. Recent news highlights record highs following the Black Hat conference and AI platform launches, though a Chinese regulatory review introduces near-term uncertainty.
The outlook for PANW remains positive given robust revenue growth, AI integration, and Wall Street's bullish consensus, but risks include elevated valuation, integration costs from acquisitions, and geopolitical scrutiny. Investors should weigh the company's leadership in cybersecurity against potential volatility from regulatory developments and high expectations priced into the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
